The in silico ADMET prediction, blood–brain barrier (BBB) penetration assay, anti-NADPH oxidase activity, reactive oxygen species (ROS) levels, and anti-glioma effects of these apocynin derivatives were evaluated. The gene discussed is FMO5; the disease is glioma.